A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults.
Fear extinction
MDMA
fear-potentiated startle
psychophysiology
randomized trial
Journal
Journal of psychopharmacology (Oxford, England)
ISSN: 1461-7285
Titre abrégé: J Psychopharmacol
Pays: United States
ID NLM: 8907828
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
pubmed:
16
2
2022
medline:
3
5
2022
entrez:
15
2
2022
Statut:
ppublish
Résumé
Fear conditioning and extinction are well-characterized cross-species models of fear-related posttraumatic stress disorder (PTSD) symptoms, and recent animal data suggest that 3,4-methylenedioxymethamphetamine (MDMA) enhances fear extinction retention. This study investigated the effect of MDMA on fear learning, extinction training, and retention in healthy humans. The study involved a randomized placebo-controlled, two-group, parallel design trial in a sample of healthy adults, age 21-55 recruited from a major metropolitan area. The experimental paradigm included a fear acquisition session followed by an extinction training session 24 hours later, and 2 hours after study drug administration. Fear extinction retention was measured 48 hours after extinction training. Participants ( Results indicated a significant main effect of session between extinction training and retention with no significant group differences. Significantly more participants in the MDMA group retained extinction learning compared to the placebo group (χ Although we did not observe the hypothesized facilitation of extinction retention, the findings from this initial human trial provide compelling rationale to continue to explore the potential for MDMA to impact extinction retention.Clinical Trials Registry Name and Identifier: Evaluation of MDMA on Startle Response (NCT0318176) https://clinicaltrials.gov/ct2/show/NCT03181763?term = MDMA&draw = 2&rank = 9.
Sections du résumé
BACKGROUND
BACKGROUND
Fear conditioning and extinction are well-characterized cross-species models of fear-related posttraumatic stress disorder (PTSD) symptoms, and recent animal data suggest that 3,4-methylenedioxymethamphetamine (MDMA) enhances fear extinction retention.
AIMS
OBJECTIVE
This study investigated the effect of MDMA on fear learning, extinction training, and retention in healthy humans.
METHODS
METHODS
The study involved a randomized placebo-controlled, two-group, parallel design trial in a sample of healthy adults, age 21-55 recruited from a major metropolitan area. The experimental paradigm included a fear acquisition session followed by an extinction training session 24 hours later, and 2 hours after study drug administration. Fear extinction retention was measured 48 hours after extinction training. Participants (
RESULTS
RESULTS
Results indicated a significant main effect of session between extinction training and retention with no significant group differences. Significantly more participants in the MDMA group retained extinction learning compared to the placebo group (χ
CONCLUSION
CONCLUSIONS
Although we did not observe the hypothesized facilitation of extinction retention, the findings from this initial human trial provide compelling rationale to continue to explore the potential for MDMA to impact extinction retention.Clinical Trials Registry Name and Identifier: Evaluation of MDMA on Startle Response (NCT0318176) https://clinicaltrials.gov/ct2/show/NCT03181763?term = MDMA&draw = 2&rank = 9.
Identifiants
pubmed: 35166140
doi: 10.1177/02698811211069124
pmc: PMC10191244
mid: NIHMS1897336
doi:
Substances chimiques
N-Methyl-3,4-methylenedioxyamphetamine
KE1SEN21RM
Banques de données
ClinicalTrials.gov
['NCT03181763']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
368-377Subventions
Organisme : NICHD NIH HHS
ID : K12 HD085850
Pays : United States
Organisme : NIMH NIH HHS
ID : P50 MH100023
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002378
Pays : United States
Références
J Anxiety Disord. 2019 Dec;68:102147
pubmed: 31669786
Psychopharmacology (Berl). 2019 Sep;236(9):2735-2745
pubmed: 31065731
Biol Psychiatry. 2011 Mar 15;69(6):556-63
pubmed: 21035787
J Psychopharmacol. 2013 Jan;27(1):40-52
pubmed: 23118021
Philos Trans R Soc Lond B Biol Sci. 2018 Mar 19;373(1742):
pubmed: 29352033
J Psychopharmacol. 2016 Dec;30(12):1248-1258
pubmed: 27562198
Neurobiol Learn Mem. 2008 Oct;90(3):504-10
pubmed: 18672079
Biol Psychiatry. 2015 Aug 1;78(3):178-85
pubmed: 25796471
Psychopharmacology (Berl). 2017 Oct;234(19):2883-2895
pubmed: 28741031
Behav Neurosci. 2008 Oct;122(5):1016-30
pubmed: 18823159
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Front Psychiatry. 2014 Jul 21;5:88
pubmed: 25101010
Psychiatry Res. 2009 May 15;167(1-2):151-60
pubmed: 19345420
Soc Cogn Affect Neurosci. 2014 Nov;9(11):1645-52
pubmed: 24097374
Behav Res Ther. 2016 Jul;82:28-37
pubmed: 27183343
Am J Psychiatry. 2005 Feb;162(2):214-27
pubmed: 15677582
Ann N Y Acad Sci. 2003 Dec;1008:112-21
pubmed: 14998877
Neuropsychopharmacology. 2020 Feb;45(3):462-471
pubmed: 31733631
Annu Rev Psychol. 2012;63:129-51
pubmed: 22129456
Ann N Y Acad Sci. 2000 Sep;914:225-37
pubmed: 11085324
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jun 8;84(Pt A):221-228
pubmed: 29524515
Learn Mem. 2006 Nov-Dec;13(6):681-5
pubmed: 17142300
Lancet Psychiatry. 2018 Jun;5(6):486-497
pubmed: 29728331
Am J Psychiatry. 2014 Jun;171(6):640-8
pubmed: 24743802
J Psychopharmacol. 2014 Sep;28(9):847-56
pubmed: 25052243
Biol Psychiatry. 2010 Dec 15;68(12):1134-40
pubmed: 20947066
Neurobiol Learn Mem. 2014 Sep;113:165-73
pubmed: 24183839
Am J Psychiatry. 2020 May 1;177(5):391-410
pubmed: 32098487
Clin Psychol Rev. 2016 Feb;43:128-41
pubmed: 26574151
Psychopharmacology (Berl). 2020 Aug;237(8):2485-2497
pubmed: 32500209
Front Psychiatry. 2019 Sep 12;10:650
pubmed: 31572236
Int J Neuropsychopharmacol. 2014 Mar;17(3):371-81
pubmed: 24103254
Neuron. 2002 Nov 14;36(4):567-84
pubmed: 12441048
Physiol Behav. 2019 Feb 1;199:343-350
pubmed: 30529341
Transl Psychiatry. 2015 Sep 15;5:e634
pubmed: 26371762
J Clin Psychiatry. 2000;61 Suppl 5:4-12; discussion 13-4
pubmed: 10761674
Front Behav Neurosci. 2011 Jul 25;5:44
pubmed: 21845177
Neuropharmacology. 2012 Feb;62(2):695-704
pubmed: 21377482
Nat Med. 2021 Jun;27(6):1025-1033
pubmed: 33972795
Neurosci Lett. 2017 May 10;649:176-180
pubmed: 27394687
Biol Psychiatry. 2007 Sep 1;62(5):446-54
pubmed: 17217927
Biol Psychiatry. 2015 Oct 15;78(8):554-62
pubmed: 24495461
J Pharmacol Exp Ther. 2007 Dec;323(3):954-62
pubmed: 17890444
Cogn Emot. 2017 Jun;31(4):687-698
pubmed: 26998883
J Anxiety Disord. 2014 May;28(4):358-62
pubmed: 24786361
Psychopharmacology (Berl). 2002 Aug;162(4):396-405
pubmed: 12172693
J Psychopharmacol. 2017 May;31(5):576-588
pubmed: 28443695